University of Colorado honors Taligen as Bioscience Company of the Year

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7^th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases. In addition, V. Michael Holers, Ph.D., Taligen's Co-Founder and Chief Scientific Officer and a Professor at the University of Colorado, Denver, was honored with the Pinnacle of Inventorship Lifetime Achievement Award for his unparalleled career as one of the world's leading experts in complement biology.

"We are pleased to have been honored by the University of Colorado for our pipeline of novel tissue-targeted complement inhibitors as they offer a truly unique approach to treating a broad array of genetic and inflammatory diseases," said Abbie Celniker, Ph.D., President and CEO of Taligen. "Taligen's progress and proprietary know-how is based on Dr. Holers' groundbreaking research in complement system biology and, in particular, the complement alternative pathway. We are pleased that Dr. Holers is being recognized by the University of Colorado for his outstanding contributions in the field. Indeed, we are honored to have him as a member of the Taligen senior leadership team as he is a critical part of our goal to make a difference in the lives of patients afflicted with complement mediated diseases."